查看完整版本: Impact of Nano Materials in Drug Delivery & Human Tissue Engineering

Impact of Nano Materials in Drug Delivery & Human Tissue Engineering

[size=3][color=DarkGreen][b]Description[/b]
.~)] P5OkM aG!EM r9F.f'A\?4n
This new market analysis report - Impact of Nano Materials in Drug Delivery & Human Tissue Engineering - provides a market driven top down approach that identifies existing products using nano based knowledge to strengthen their capabilities and provides a description of the product’s market niche to pinpoint future trends. A recent analysis of more than 200 commercially available products that use nano-based technological enhancements in the pharmaceutical, medical or healthcare field is reinforcing the notion that “incremental” modifications of existing drugs, drug delivery devices and tissue engineering products enhanced by nano innovations is beginning to harvest revenue.
~.J"A)~u6a L v(A-x rO?|.]0k
[b]About the Author:[/b]
:p%iJ8T,{ T(CMa#RS
Gautam Thor received his PhD in Neurobiology in 1983 from The Tata Institute of Fundamental Research, India where he got interested in the study of the growth of the visual system that has resulted in the recent formation of Coded Imagery to commercialize some aspects of these studies. He has also researched at UCSD in the field of Neuroimmunology and is the author of numerous scientific and medical publications through NeuroConsultants, and, is internationally recognized for his expertise in human diagnostics. 6uLj#W!? t5y
P:ab
\ J.PY7Yg-YM
[b]Table of contents[/b]
G z;B KcQ
&| G!QwW]_){:K Chapter 1: Executive Summary]@)@m5Ww

2KQ5Vdm3S
?6w}\T:R(m Chapter 2: Nanomaterials Relating to the Drug Discovery,Hp`
t
G2g~vM [
Drug Delivery & Tissue Engineering Industries Nanoparticles1VPWk*x7c
Quantum Dots (QDs);Qiy2kQ0| _6~7co
Gold Colloids C:dWq s
I]E
Gold & Quantum Dots for Molecular Diagnosticsy]}_I#|$F-ys1|j
Magnetic Nanoparticlesj8K%jO&x$^Y6Sz
Dendrimers \q#N7L/vD.z.I
Nanoshells
&o$dYYxN\dn8g!U Carbon Nanotubes & Nanotube MatricesJ t5t}/C
Multiplex Molecular Tagging with QDs, Nanotags, and Nanoprisms
ejp,sa NanobarcodesU P2\2h5M]1\
Biobarcode Assay for Proteins(F{;E_5I
Nanoparticle-based Colorimetric DNA Detection Method
9@ Cwn9HtDc&x Liposomes7w u5?,sq
Multilayered Nanoparticlesk/U/[$qx

C_,P6WrJ"p0m9Rw New MRI Nanomaterials as Probes for Imaging Agents—Gadolinium in Fullerenes & Quantum Dots!Ojeo yBaZ-J
Molecular Imaging
0qD*_2}[Y;O5I7JWt /h&mTx7fj
Drug Delivery and Therapeutics—Bioavailability through Nanocrystals'b~&e7Rk5rMn
Rexin G—An FDA Approved Targeted Delivery System (TDS)
t2jd?5X%BM Nanocrystals in Immunohistochemistry & Nanomedicine
hMM d,?@w Fullerenes for Delivering Therapeutic Molecules
| Z Mv z~*vn M Injectable & Topical Platforms Enhanced by Nanoparticluate Technologies
:G!EF&{-b(]0z4H!kD Nanotechnologies with Biochips & Protein chips
6S;k+b/x
zB0}Qv @1q.A?+g r7j6e)Z
Nano Biosensors9SB4_L3`)o
Nanowire Biosensors using Boron-doped Silicon Nanowire,e B
`#O~Uq
Viral NanosensorOT4Dt1D1R[d
Probes Encapsulated by Biologically Localized Embedding Nanosensors*Mx0WOhoHZ!~
New Nano-based Biosensor Technologies in MarketY2\R4TB:s
7MOP?$Z9qR
Nano Tissue Engineering—Nanophase Biomaterials(qB3m;`Gd6|(e!_
Biocompatible Polymer Nanofibers
"?$bLvT3`/w;|#{
SD4a[7C!D'V j Nanochemicals Against CancerysJ
u-_[ z!M"v?
Nanodrugs and Companies Targeting Cancer
$BR8Zd'~ Nanobiotechnology’s Contributions to the Pharmaceutical/Medical Sectors:@#N;\0UY cL;g3I
hs'sy(~'J/O.e
Chapter 3: Commercial Pharmaceutical & Tissue EngineeringD!bg#[.H$S[!r&f0iI'x
Product Applications Using Nano Materials
} t%Y9Odjm-p Nano Technology and the Pharmaceutical/Tissue Engineering
K,_hOT5{ @d Product Applications Market in 2005
J&v Ir"f+r,p8Vk Nanoengineering and Emerging Nanotechnology
OaV@;eHaBTA Nanoparticles
[ {%Mi;?b Carbon Nanoparticles and Nanotubes Market
{RRF8n &`S_,_6G!^F
Medical & Healthcare Diagnostic Devices Markets
_*i/qPd Reporter Molecules and Molecular Tags for Biomolecular Detection
&V6Y#G2R?r9y0y'`we Biosensors
:E8aURE3~(D @3u Contrast and Imaging Agents for MRI and PETjpV_Q t-q
Nanobiotechnology Utility in the Drug Discovery and Delivery Process.Q&oQjem+_ UL
Solubilizing Pre-existing Drugs and Enhancing Controlled Drug Delivery
jGx`c_ Improved Drug Formulations
:Iy%Hy0H%o Controlled Released Drugs'r8]-C HP&w(szU
Multifunctional Drug Delivery Platformsl'S'Hc,sB9\
Targeted Drug Delivery PlatformsT.dZ \*f
Targeted Drug Delivery
Hc*`!zFc Devices for Targeted Drug Delivery
3R1q!@Vqp&K #o2]~9N1mV:^
Medical & Tissue Engineering Nano Material-based Products in 2005l_F)l7y)pc3Ox(J
Wound Dressings and Wound Repair
_B~3e$C `^!t Stents and Catheters
EX%meAq)T Implants and Prosthetics]Y;f%x#Al h[

v!L9a,Q8@)_&K7GqL:l] Future Markets of Pharmaceutical and MedicalLJv
QhECS
“Nano Material-based” Products
n7v\ofKO Ongoing Clinical Trials using Nano material-based drugsT#}?
~]ah5|I
National Nanotechnology Advisory Panel Evaluation of the US Nano
fpF(M2w Sector Markets

D)S.G+s&n3K ;o8Fd:s9Q1Qk H
Chapter 4: Health, Environmental, and Societal Impacts ofs\I,g7v5o
Nanoparticles
qLe|Y Free Nanoparticles d Y\)o$ibk
Free Nanoparticle Safety Needs To Be AssessedgrL2Fs
Potential Exposure Routes
/Qw7p"W(VE3nB Nanoparticles Can Be Toxic by Inhalation or through Skin Exposuref5OzA/[B7]
Factors Affecting Deleterious Effects of Nanomaterials
OEAo}]:z Eco-toxicity—On the Environment and on Other Species
$H'X)~5\|;}7a0jv L Possible Adverse Health Issues
d e9E%Q;q*qI)[-l
]Sl s(b W Regulatory Issues of NanotechnologyPxH1V tI3xS'{q
Royal Society & Royal Academy of Engineering July 2004 UK Report;[,G.xl s3C:G0uh,B
The US FDA
&I%`7z"xf$Q(R Future ConsiderationsQE(u
xl
Social Science IssuesH%TmQG z*s}d;P/k
Societal Impacts
N!K*M9`'f#n7_!y9u3Lx Personal Safety versus Covert SurveillanceIZ5\we+`0K8Y
Is the Science Fiction Larger than the Science of Nanotechnology?3s8A,dibC Z

+y v7TT~[Lp;| Chapter 5: Global Investments by Private and Federal Resources
"bi;x:pL+q] Private Funding Accounts for Almost 40-50 % of Investment in the Nanotechnology SectorR/n~4Ip@8r-|
Global Distribution of Funding Sources of Nanotechnology
k mI0Y!a Private Venture Capital Funding in the US MarketAu8l[,m
Similarities between Nanotechnology, Semiconductor Industry, and DNA Technologies

UJsEy,?5]cb Patents as Indicators of the Maturity of Nanotech Investments
-l6r1D~9zQ}Hj Big Pharma’s Stumbling Block—dying Patents2gC"n@9G$|\t
Global Distribution of Patents and Academic Publications in Nano Areas— The Rise of China6d6Eja.Vxdr
G'H9C!h(}+~c"t
World Leaders in Nano Investment—US, Japan, EU & China|~]z;^^/r
United States has invested $47 Billion Since 2001
g
~ r8k%w8S LAi9r Japan Spent $800 Million for Nanobiotechnology In 2005]G4U'Rz$x6G
China will have Invested $600 Million by 2007
sU7\ k*g&B u Investments by Other Asian Countries
%Ut%\ lcVY $1 Billion from Germany, France UK & Sweden\9`tV p[e
Nanotechnology Global Investment was Approximately $9 Billion in 20055h6}gU#a9~aN
Chapter 6: Nanobiotechnology Companies
R]xV]c9W!U Nano Material Manufacturing Companies to Watch
3Yz8d~"H Dendrimer, Fullerene & Nanotube-based Companies(@|A:O UK(z \:Zz
Nano Arrays & Molecular Tag CompaniesW;g/Mp1yuvV(w
List of Nanobiotechnological Companies
t v8L/{+W:i:v 0P|+d8Q/Lz"] f
Chapter 7: Company Profiles
&R9aLk.]SR $u u_tC)|WZ8Fq
Table of Exhibits:
(N?5M&sdj ^ TY
lq t#c;f#\"s
Exhibit 21 A Dendrimer Nanoparticle Complexa*Q.{(bIXe
Exhibit 22 Structure of a Carbon NanotuberT c^h]
Exhibit 23 PCR of a Biobarcode Assay with Nanoparticles
1])p8R%u;_D/B Exhibit 24 A Drug Carrying Liposome
&{J+ipDypJ6cG Exhibit 25 A Model of the C60 Buckministerfullerene^s[.Atd uWXy1}:R
Exhibit 26 Boron-doped Silicon Nanowire,X"o^)C+lj^m
Exhibit 27 Nanotech Applications in the Fight Against Cancer
5`:{7m$W&a%gC#mNB%q Exhibit 28 Nanotechnology Tools and Platforms that Affect the Pharmaceutical & Medical Industries5{
U P7q]
Q`4q"rb
Exhibit 31 Nano-enhanced Pharmaceutical Nano Products
D"|9h_9~&Y/bf Exhibit 32 Medical/Tissue Engineering Nano Products in 2005
P
[Pf8V}6S ?;R Exhibit 33 Nanotechnology Application Markets
b,lK/GtGJn Exhibit 34 2005 Nanoparticle Based Products
O-R1[bJ5YRzv Exhibit 35 Number of Nanomaterial Companies"S&]5FMi7@BF BV
Exhibit 36 Nanomaterials and Nano Tool Market Forecast
8X"fb`"W4^ys6x5A+Vp Exhibit 37 Reporter Molecules and Molecular Tags for Biomolecular DetectionNyf5n j#E,t
Exhibit 38 Biosensor-based DevicesI1u6UOp|bh
Exhibit 39 MRI and PAT Contrast and Imaging Agents*DP`Kq KB
Exhibit 310 The Pharmaceutical Drug Discovery Process!})K_5r4Y"ba*yi
Exhibit 311 Examples of Nano-enhanced Drug Discovery and Delivery Platforms
t?/tgV&e Exhibit 312 Improved Formulations of Approved Drugs
,W&?n!s?[(yV Exhibit 313 Nano-based Drug Delivery Platforms
+~
S]*z*kq Exhibit 314 Controlled Release Options WVFqDs:K@.k_
Exhibit 315 Multifunctional Drug Delivery Applications
!['^"~yz5F z Exhibit 316 Targeted Drug Delivery Platforms
9NI/J2AT3c(]2[gF Exhibit 317 Devices for Targeted Drug Deliveryb!j3X;|(^0`
Exhibit 318 Tissue Engineering Applications
5B}q{'gn-{Hl-v Exhibit 319 Wound Dressings and Wound Repair
(m_R6VE2u%X Exhibit 320 Stents and Catheters
:V(Tr6FG2Sy} Exhibit 321 Dental and Prosthetic Implants*n0h/V9C4T#pk
Exhibit 322 Current Clinical Trials using Nano Material based Chemistries
3~N8e,y/H$WCU Exhibit 323 NNI Evaluation of Nanosector Markets
Ib4t+j ?&F Exhibit 41 Dimensions of Biological Molecules in the Nanometer Rangek0U_Wj1s
Exhibit 51 The Global Nanotechnology Market
MQq_ _ Exhibit 52 Global Venture Capital Investment into Nanobiotechnology
l%nl0dr!Y}S Exhibit 53 VC and Government funding for Japan, USA and EU in Terms of Numbers of Players
g"iX
o{k Exhibit 54 Number of Nanotech Related Patents't"E'u?(Z+p
Exhibit 55 Publications in ISI Web of Science Databasesde5Sh/~Xf
Exhibit 56 Global Government Funding of Nanotechnology0W"z0m&[7E
Exhibit 57 US 2006 Budget of Nanotechnology Segmentst-pZ8u`1z'w'k5E%DP
Exhibit 61 Companies Leading the Field in Arrays and Molecular Tags
2[LL9y,w9f\O j Exhibit 62 List of Nanotech Companies
w/Xx:zaz"P
-I.m3y.qT [b]Summary of the report[/b]C']jc%L(y,S$^ x

6R#s?Vx'_ ]A-] [/color][/size][size=3][color=DarkGreen]This reporthighlights the impact of Nanotechnology in the development of newbiomaterials designed, using “nanoscale” properties, to enhancedeveloping platforms for drug development and delivery. It alsodiscusses the generation of new drug device combinations, and biophasematerials for tissue engineering products, both being the forerunnersin the nanotechnology field that are currently attracting revenue.Today, nanoparticles such as colloidal gold, quantum dots, liposomes,dendrimers and fullerenes are being used in pharmaceutical drugdiscovery and in formulations for encapsulating drugs for drug delivery.&r+sq3I*]
"K,| IB#e9v4}V
Somenanoparticulates such as fullerenes and dendrimers can be modified byprecise grafting of active chemical groups and be used as drugsthemselves. Products using nanostructured materials for drug delivery,tissue engineering and MRI imaging have begun to enter clinical phasetrials.E)x6MdLf B0sH
An important aspect of biomedical and pharmaceutical relatednanotechnology is that the systems are designed to be multifunctionaland can be used to meet diverse diagnostic or therapeutic requirements.Improved efficacy, enhanced solubility, and lower toxicity bynanobiotechnological innovations have been demonstrated for a fewexisting drugs and FDA approval of Abraxane in January 2005 isexpected, to be followed by INDs for several clinical drugs in PhaseIII. Near term forecasts indicate that products that will reach themarket in 2006 will include the first nanoparticulate drugs fromSkyePharma (propofol), Nanobio (NanoHpx Herpes), NovaVax (Estrasorb),and a dermatological product from C Sixty based on fullerenes.Engineering pre-existing drugs onto nano-enabled scaffolds is also astrategy that will be used to extend the patent lives ofpharmaceuticals.
S3n`7e#i3Q 'ac8[[m-|L
There is legitimate concern regarding thesafety of nanoparticles introduced in the human body or released intothe environment. Research is underway to explore these considerations.As nanobiotechnology products begin to enter the market, the FDA isexpected to promulgate the necessary regulatory safety guidelines. Themain concern surrounding nanotechnology is that materials behave verydifferently at the nanoscale.h@-\&[V
Annual global funding of $25 billionsince 2000 is a measure of the future value anticipated across theentire nanotechnology field—predicted to reach $1 trillion by 2015 andrequire 5 million trained, specialized workers in the United Statesitself. However the current market size estimates according to areas ofapplication indicate marginal incremental near term revenues fromnanobiotechnology per se. Though the medium (5 -10 year) and long term(20+ year) forecasts are the timelines that can be used to justify theunprecedented infusion of funding, current nano material applicationsdo seem to have begun to justify the ROI (Return of Investment) thatprivate and public funding sources are anticipating from this
;Xi(|%q%aZ
? on&]g Xoo [/color][/size][size=3][color=DarkGreen][color=DarkGreen][b]More information, please visit http://www.researchandmarkets.com/reports/c43614[/b][/color]
%]N8J
C"j+G0Ih~ [/color][/size]

这么好资料，顶H.Asp~b
楼主能否给我发一份呀&l_C"O~U9l
[email]wangyongqiangge@56.com[/email]$y [`']:S8D8Tj
xiexiele
sd})V$T thanks

能否给我发一份？谢谢！JX,pz? G[&t+k&lc
[email]choupi.rong@yahoo.com.cn[/email]

回复 #3 choupirong 的帖子

这个报告是收费的。我们这里也没有，只是介绍。欢迎大家分享！